Inozyme Pharma has appointed Kurt Gunter as chief medical officer. Gunter most recently held the position of chief medical officer, cell therapy and head of regulatory affairs at Athenex. Before that, he was chief medical officer at Kuur Therapeutics and a medical officer at the Food and Drug Administration’s Center for Biologics. At Inozyme, he’ll help develop the company’s pipeline for rare mineralization disorders.
“Kurt’s experience across the entirety of the drug development process will be invaluable as we advance INZ-701 in our ongoing Phase 1 / 2 clinical trials in patients with ENPP1 deficiency and ABCC6 deficiency and prepare for our later-stage studies,” Axel Bolte, co-founder, president and CEO of Inozyme, said in a statement.